Olive et al. provided evidence that, in KRAS and p53 mutant pancreatic adenocarcinoma xenografts in a gemcitabine-resistant mouse model, chemotherapy does not reach tumor cells due to poor tumor vascularization [59]. Here, KRAS is linked to pancreatic adenocarcinoma.